Kite Pharma Priced, Nasdaq: KITE
Biotech developing cancer immunotherapies with the National Cancer Institute.
Industry: Health Care
First Day Return: +70.6%
KITE
Biotech developing cancer immunotherapies with the National Cancer Institute.
| IPO Data | |
|---|---|
| IPO Date | 06/19/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $128 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Santa Monica, CA, United States |
| Founded | 2009 |
| Employees at IPO | 19 |
| Website www.kitepharma.com | |
IPO News for Kite Pharma
Kite Pharma (KITE) Performance
